Chapter 30 • Hematopoietic cell transplantation (HCT) is a potentially curative treatment for a variety of hematopoietic, immune, metabolic, and malignant diseases. • Hematopoietic stem cells for transplantation can be collected from bone marrow, peripheral blood, or umbilical cord blood. • With the advent of unrelated donor, haploidentical, and cord blood transplantation, virtually every patient can now have a suitable donor. • Reduced-intensity conditioning regimens are associated with lower treatment-related mortality and allow for transplantation in elderly and patients with comorbidities who are not candidates for myeloablative HCT. • Allogeneic HCT is most frequently performed for patients with acute and chronic leukemias, myelodysplastic syndromes, immune deficiencies, metabolic disorders, and bone marrow failure states. • Autologous HCT is usually performed as part of the initial treatment for multiple myeloma, relapsed Hodgkin and non-Hodgkin lymphoma, and select solid tumors. • Common complications of HCT include regimen-related organ toxicity, graft rejection, graft-versus-host disease, infections, and secondary malignancies. 1. All of these conditions increase the risk of graft-versus-host disease (GVHD) except:
Hematopoietic Stem Cell Transplantation
Summary of Key Points
